NeoGenomics, Inc. Common Stock (NEO) Stock
Key stats
- Market cap
- $2.18B
- Price / Earnings ratio
- -67.9x
- EPS (TTM)
- -$0.24
- Volume
- Loading
- 52-week high
- $20.15
- 52-week low
- $7.07
Source: third-party data provider, as of November 13, 2026
Compare with NEO
Recent news

What NeoGenomics (NEO) Said on Its Q3 Earnings Call
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NEO

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NEO

NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics Reports Third Quarter 2026 Results
NEO

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NEO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.66
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.03
- SMA 50
- $17.59
- Price below SMA 50
- EMA 50
- $17.01
- Price below EMA 50
- SMA 200
- $12.95
- Price above SMA 200
- EMA 200
- $13.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

What NeoGenomics (NEO) Said on Its Q3 Earnings Call
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NEO

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NEO

NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics Reports Third Quarter 2026 Results
NEO

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NEO

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NEO

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
NEO

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NEO

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NEO

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEO

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
NEO
News tone: automated (AI) classification of the article's content, not a price prediction.
About NeoGenomics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony P. Zook | CEO & Director | 1961 |
| Mr. Warren Stone | President & COO | 1973 |
| Mr. Abhishek Jain | Executive VP & CFO | 1976 |
| Ms. Elizabeth A. Floegel | Chief Digital & Information Officer | 1976 |
| Mr. Gary Passman | Chief People & Culture Officer | — |
| Mr. Gregory D. Aunan | Senior VP & Chief Accounting Officer | 1969 |
| Mr. Andrew Frederick Brackmann C.F.A. | Vice President of Investor Relations | — |
| Mr. Clarence Cooper Esq. | Vice President of Compliance & Privacy | — |
| Dr. Andrew A. Lukowiak Ph.D. | Chief Innovation Officer | 1972 |
| Priya Vedaraman | Senior Vice President of Finance | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.66
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.03
- SMA 50
- $17.59
- Price below SMA 50
- EMA 50
- $17.01
- Price below EMA 50
- SMA 200
- $12.95
- Price above SMA 200
- EMA 200
- $13.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $23.25
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.2 | +4.1 | ||||||||||
| 2022 | -36.1 | -7.3 | -42.3 | -23.7 | -13.6 | +1.2 | +20.9 | -0.8 | -14.5 | -12.6 | +46.5 | -17.3 |
| 2023 | +30.7 | +34.8 | +5.0 | -13.4 | +16.7 | -9.0 | +9.8 | -14.3 | -18.9 | +17.8 | +32.0 | -14.8 |
| 2024 | -6.9 | +5.4 | -1.6 | -9.6 | -1.8 | +2.6 | +27.3 | -5.6 | -7.1 | -1.6 | +26.6 | -8.4 |
| 2025 | -13.3 | -28.0 | -0.9 | -31.6 | +0.3 | +2.0 | -34.7 | +70.2 | -12.4 | +12.0 | +23.7 | -2.2 |
| 2026 | +2.6 | -20.1 | -21.9 | +19.5 | +11.4 | +39.8 | +2.1 | +13.1 | +5.2 | -2.2 | +2.1 |



